PF-06741086 + PF-06741086 + PF-06741086 + PF-06741086

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Hemophilia A or B

Conditions

Hemophilia A or B

Trial Timeline

Mar 8, 2017 → Dec 3, 2018

NCT ID

NCT02974855

About PF-06741086 + PF-06741086 + PF-06741086 + PF-06741086

PF-06741086 + PF-06741086 + PF-06741086 + PF-06741086 is a phase 2 stage product being developed by Pfizer for Hemophilia A or B. The current trial status is completed. This product is registered under clinical trial identifier NCT02974855. Target conditions include Hemophilia A or B.

What happened to similar drugs?

20 of 20 similar drugs in Hemophilia A or B were approved

Approved (20) Terminated (3) Active (0)

✅EmicizumabRocheApproved

✅BenefixPfizerApproved

✅Nonacog alfaPfizerApproved

✅moroctocog alfa (AF-CC) (ReFacto AF)PfizerApproved

✅Recombinant Factor IX CoagulationPfizerApproved

✅Moroctocog alfa(AF-CC)PfizerApproved

✅Factor IX recoveryPfizerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02974855	Phase 2	Completed	Mar 8, 2017	Dec 3, 2018	Hemophilia A or B

Competing Products

20 competing products in Hemophilia A or B

See all competitors

Product	Company	Stage	Hype Score
Emicizumab	Chugai Pharmaceutical	Phase 3	40
Emicizumab	Chugai Pharmaceutical	Phase 3	40
Emicizumab + rFVIIa + aPCC	Chugai Pharmaceutical	Phase 3	40
Human Coagulation Factor VIII	Chugai Pharmaceutical	Phase 3	47
Emicizumab	Chugai Pharmaceutical	Phase 3	47
Emicizumab + Factor VIII (FVIII)	Chugai Pharmaceutical	Phase 3	40
Emicizumab	Roche	Phase 3	40
HEMLIBRA	Johnson & Johnson	Pre-clinical	26
Emicizumab	Roche	Phase 3	40
Emicizumab	Roche	Approved	47
Emicizumab	Roche	Phase 3	44
SPK-8011QQ	Roche	Phase 1/2	39
NXT007	Roche	Phase 1/2	39
Emicizumab Injection	Roche	Phase 2	35
Bypassing Agents + FVIII Replacement	Roche	Pre-clinical	26
Nonacog Alfa (Genetical Recombination)	Pfizer	Pre-clinical	26
Refacto AF	Pfizer	Pre-clinical	18
PF-06838435/ fidanacogene elaparvovec	Pfizer	Phase 3	44
ReFacto AF	Pfizer	Phase 3	40
Nonacog alfa + Nonacog alfa	Pfizer	Phase 3	40